-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in Hong Kong stocks | Keji Pharmaceutical-B (02171) rebounded the market and rose more than 9%, Kailimei became the first solid tumor CAR-T product in the commercial insurance innovative drug catalogue

Zhitongcaijing·11/17/2026 02:41:04
Listen to the news

The Zhitong Finance App learned that Keji Pharmaceutical-B (02171) reversed the market and rose more than 9%. As of press release, it rose 7.08% to HK$10.74, with a turnover of HK$1987.07 million.

According to the news, the 2026 commercial health insurance innovative drug catalogue was announced on November 14. Keji Pharmaceuticals' Kalimei® (shurikiolensis injection) was included in the commercial insurance innovative drug catalogue, making it the first solid tumor CAR-T cell treatment product to be included in the catalogue since it was established.

According to public information, Kalimei® is the world's first autologous CAR-T cell therapy product targeting Claudin18.2 protein, and is also the world's first car-T cell therapy variety approved for marketing for solid tumors. The drug was approved for marketing by the State Drug Administration in June 2026. It is used to treat advanced gastro/esophagastric junction adenocarcinoma (G/GEJA) that is positive for Claudin 18.2, negative for human epidermal growth factor receptor 2 (HER2), and failed at least second-line treatment.